2019 ACR/ARP Annual Meeting

November 8-13, 2019. Atlanta, GA.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 1182

Fluorescence Optical Imaging in the Diagnosis of Individuals Suspected of Arthritis Development – a Probabilistic Approach
Abstract Number: 77

Flux Analysis Reveals Influence of Rab4 Expression on Mitochondrial and Pentose Phosphate Pathway Metabolism of Lupus T Cells
Abstract Number: 2616

Forced Vital Capacity Trajectories for Systemic Sclerosis-associated Interstitial Lung Disease—Analysis from the University of Michigan Scleroderma Cohort
Abstract Number: 1969

FOXO1 Is Required for Human Osteoclast Differentiation
Abstract Number: 2204

Fragility Fractures in a Community Setting: Clinical Characteristics, Care Gaps, and Outcomes
Abstract Number: 1316

Frail Patients Have Less Pain After Total Hip Replacement
Abstract Number: 1317

Frail Patients Have Worse Function After Total Knee Replacement
Abstract Number: 325

Frailty and Sarcopenia in Inflammatory Rheumatic Disease
Abstract Number: 1600

Frailty and Sarcopenia in Women with Systemic Lupus Erythematosus
Abstract Number: 2460

Frailty in Ankylosing Spondylitis, Psoriatic Arthritis, and Rheumatoid Arthritis: Data from a National Claims Database
Abstract Number: 2142

Frailty in Systemic Rheumatic Diseases: A Systematic Review
Abstract Number: PP08

Framework for Enhancing Patient-Physician Communication in the Context of Rare Disease
Abstract Number: 919

Free Interlukin-18: A New Promising Biomarker for Systemic Juvenile Idiopathic Arthritis and Macrophage Activation Syndrome
Abstract Number: 558

Frequency and Characteristics of Inflammatory Bowel Disease in Spondyloarthritis with Biological Therapy: Study of 270 Patients from the Same Center
Abstract Number: 2522

Frequency and Early Prediction of Hydroxychloroquine Induced Retinopathy in SLE

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].